IDiyas

For the Inventor, By the Inventor

Lebanon, CT, United States of America

Randall James Gallaschun

USPTO Granted Patents = 16 

 

 

Average Co-Inventor Count = 2.4

ph-index = 3

Forward Citations = 59(Granted Patents)


Location History:

  • Norwich, CT (US) (1999)
  • Lebanon, CT (US) (2003 - 2024)

Company Filing History:

goldMedal10 out of 49 
 
Hydra Biosciences, Inc.
 patents
silverMedal6 out of 4,455 
 
Pfizer Corporation
 patents

Years Active: 1999-2024

Loading Chart...
Loading Chart...
Loading Chart...
16 patents (USPTO):
1. 11958854 - Substituted xanthines and methods of use thereof (2024-04-16),
2. 11208409 - Substituted xanthines and methods of use thereof (2021-12-28),
3. 10399982 - Substituted xanthines and methods of use thereof (2019-09-03),
4. 9969736 - Substituted xanthines and methods of use thereof (2018-05-15),
5. 9745272 - Quinazoline-2,4(1 H,3H)-dione derivatives (2017-08-29),
6. 9447114 - Thieno- and furo[2,3-d]pyrimidine-2,4[1H,3H]-dione derivatives (2016-09-20),
7. 9440983 - Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione derivatives (2016-09-13),
8. 9440973 - Pyrido[3,4-d]pyrimidine-2,4(1H,3H)-dione derivatives (2016-09-13),
9. 9440972 - Pyrido[2,3-d]pyrimidine-2,4(1 H,3H)-dione derivatives (2016-09-13),
10. 9359359 - Substituted xanthines and methods of use thereof (2016-06-07),
11. 8686043 - Heterocyclic sulfonamides, uses and pharmaceutical compositions thereof (2014-04-01),
12. 8278457 - Heterocyclic sulfonamides, uses and pharmaceutical compositions thereof (2012-10-02),
13. 6552015 - Azabicycloalkane derivatives and therapeutic uses thereof (2003-04-22),
14. 6531468 - Diazabicyclooctane derivatives and therapeutic uses thereof (2003-03-11),
15. 6521630 - Tetrahydroquinazoline-2,4-diones and therapeutic uses thereof (2003-02-18),

Title: Inventor Profile: Randall James Gallaschun

Introduction

Randall James Gallaschun is a prominent inventor based in Lebanon, Connecticut, USA, known for his significant contributions to the field of medical and pharmaceutical innovations. With an impressive portfolio of 16 patents, Gallaschun has focused his research on developing compounds and methods that target critical biological pathways.

Latest Patents

Among his latest innovations are two patents related to substituted xanthines, which detail compounds, compositions, and methods specifically designed for inhibiting the TRPC5 ion channel. These developments are particularly relevant for addressing various disorders associated with the TRPC5 channel, showcasing Gallaschun's commitment to advancing therapeutic options in this area.

Career Highlights

Throughout his career, Gallaschun has held positions in reputable companies, including Hydra Biosciences, Inc. and Pfizer Corporation. His work within these organizations has allowed him to leverage his expertise in pharmaceutical research and development, further driving innovation in drug discovery and therapeutic interventions.

Collaborations

Gallaschun's success as an inventor is also enhanced by his collaborations with talented colleagues such as Bertrand Leo Chenard and Anton Franz Joseph Fliri. These partnerships have fostered a dynamic environment for idea exchange and product development, significantly contributing to the advancement of their projects.

Conclusion

Randall James Gallaschun stands out as a valuable inventor whose work in the pharmaceutical industry is marked by a robust patent portfolio and meaningful collaborations. His ongoing research and development initiatives promise to lead to impactful solutions for medical challenges related to the TRPC5 ion channel. As innovations continue to emerge from his efforts, Gallaschun remains a key figure in the landscape of pharmaceutical inventors.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…